Related Experiment Video

Updated: Sep 11, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance

Xiyuan Luo1,2,3, Feihan Zhou1,2,3, Yuemeng Tang1,2,3

  • 1Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100023, China.

Chinese Medical Journal
|August 18, 2025
PubMed

Insights

KRAS mutations drive invasive cancers and treatment resistance. Understanding resistance mechanisms and developing new inhibitors are crucial for effective precision oncology strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • The Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation is a frequent driver in many cancers, associated with poor prognosis.
  • Despite advances in KRAS inhibitors, acquired drug resistance remains a significant clinical hurdle, limiting therapeutic efficacy.
  • Identifying the molecular basis of KRAS inhibitor resistance is essential for improving patient outcomes.

Purpose of the Study:

  • To comprehensively review the KRAS mutation landscape and its role in cancer.
  • To summarize the development and clinical progress of small molecule KRAS inhibitors.
  • To explore strategies for overcoming acquired resistance to KRAS-targeted therapies.

Main Methods:

  • Literature review of peer-reviewed articles and clinical trial data.
  • Analysis of mutation profiles and molecular mechanisms of KRAS activation and resistance.
  • Synthesis of current research on KRAS inhibitors and resistance pathways.

Main Results:

  • KRAS mutations are diverse across cancer types, influencing tumor behavior and therapeutic response.
  • Several small molecule KRAS inhibitors targeting specific mutations are in clinical development, showing promise.
  • Emerging resistance mechanisms include bypass signaling pathways and secondary mutations.

Conclusions:

  • Targeting KRAS is a key strategy in precision oncology, but resistance necessitates ongoing research.
  • Developing combination therapies and novel inhibitors is critical to overcome acquired resistance.
  • Future directions focus on patient-centric approaches to manage KRAS-mutated cancers effectively.
Keywords:
Drug resistanceInhibitorsKirsten rat sarcoma viral oncogene homologOncogenic signalingMutationsOncogenic virusPrecision medicineSignal transductionsTarget therapy

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.2K